02320nas a2200229   4500000000100000008004100001260002100042653002100063653003500084653002400119653002200143653002500165653002600190100001100216700001200227245008700239856008800326300001200414490000700426520164300433022001402076       2025                            d  bGSC Online Press10aHansen's disease10aBorderline tuberculoid leprosy10aChronic hepatitis B10aMultidrug therapy10aImmune dysregulation10aPeripheral neuropathy1 aSaha D1 aYadav L00aTwo Foes, One Host: The Poignant Coexistence of Hansen’s Disease and Hepatitis B  uhttps://magnascientiapub.com/journals/msarr/sites/default/files/MSARR-2025-0122.pdf  a157-1640 v153 a<jats:p>Leprosy (Hansen's disease) is a chronic infectious condition caused by Mycobacterium leprae, characterized by skin lesions and peripheral nerve involvement, often leading to functional and aesthetic complications. Chronic hepatitis B, caused by hepatitis B virus (HBV), is a hepatotropic infection that can range from asymptomatic carrier states to severe liver disease including cirrhosis and hepatocellular carcinoma. We report a rare case of a 29-year-old male from Uttar Pradesh presenting with a solitary hypopigmented patch over the right knee accompanied by hypoaesthesia, clinically and histopathologically confirmed as borderline tuberculoid leprosy. Incidentally, the patient was also diagnosed with chronic hepatitis B infection during initial evaluation. The patient has been on multidrug therapy for leprosy per WHO protocols while being monitored for HBV without antiviral initiation due to absence of active viral replication or significant liver damage. This dual coexistence underscores the complexities of managing patients with simultaneous infections that modulate immune function differently: leprosy impairing cell-mediated immunity and chronic HBV causing defective adaptive immune responses. Awareness of such co-infections is vital to tailor therapy and avoid drug-induced hepatic toxicity. Hepatitis B screening before starting leprosy treatment is emphasized to optimize management. This report adds to limited data on concurrent Hansen's disease and chronic hepatitis B, highlighting the need for further research into their immunopathological interactions and comprehensive clinical approach.</jats:p>  a2582-9394